N-Nitroso Varenicline
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

2755871-02-2N-Nitroso Varenicline

● In Stock

Catalogue No.:VE006503
CAS No.:2755871-02-2
Mol. Formula:C13H12N4O
Mol. Weight:240.26 g/mol

Additional information on CAS 2755871-02-2

Parent drug

Varenicline

IUPAC Name

8-nitroso-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline

Pharmacopeial Synonyms

N/A

Synonyms

Varenicline Impurity 9; Varenicline Nitrosamine VRN-5000 Impurity

Smiles

O=NN1CC(C2)C3=C(C2C1)C=C4N=CC=NC4=C3

InChI

InChI=1S/C13H12N4O/c18-16-17-6-8-3-9(7-17)11-5-13-12(4-10(8)11)14-1-2-15-13/h1-2,4-5,8-9H,3,6-7H2

Shipping Condition

Ambient Temperature

FDA Potency Category 3 NDSRI

400 ng/day is the U.S. FDA’s current Acceptable Intake (AI) limit for N-nitroso-varenicline (NDSRI). Refer to the FDA nitrosamine page for the latest guidance.

Description

Varenicline Nitrosamine VRN-5000 Impurity, also designated Varenicline Impurity 9 and N-Nitroso Varenicline, is a nitrosamine-related process or degradation impurity associated with the varenicline scaffold. CAS 2755871-02-2; molecular formula C13H12N4O; molecular weight 240.26 g/mol. As an N-nitroso species, it warrants consideration under nitrosamine risk assessment and ICH M7 principles because such entities may present mutagenic concern at trace levels. Structural confirmation and quantification typically rely on LC-MS/MS, with complementary high-resolution MS and, where appropriate, GC-MS after derivatization or concentration. Its presence may arise from nitrosating conditions during synthesis, workup, or storage.

Request a Quote

« * » indique les champs nécessaires

Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Products quotation
Name
Url